Oral etoposide in relapsed or refractory Ewing sarcoma: A monoinstitutional experience in children and adolescents

Marta G. Podda, Roberto Luksch, Nadia Puma, Lorenza Gandola, Carlo Morosi, Monica Terenziani, Andrea Ferrari, Michela Casanova, Filippo Spreafico, Cristina Meazza, Serena Catania, Elisabetta Schiavello, Veronica Biassoni, Stefano Chiaravalli, Maura Massimino

Research output: Contribution to journalArticle

Abstract

Aims: To assess the efficacy and toxicity of low-dose oral etoposide (VP) 16 in relapsing/refractory Ewing sarcoma. Methods: The records of all patients treated at our department between 1989 and 2012 for relapsing/refractory Ewing sarcoma who received oral VP-16 were analyzed. The dose was 40 mg/m2 daily for 21 consecutive days in every 28. Response was assessed after 2/3 cycles according to Response Evaluation Criteria in Solid Tumors 1.0. Results: A total of 46 of 58 patients completed at least 2 cycles; 12 suspended the treatment earlier due to rapid disease progression. The patients' median age at diagnosis was 14 years and 25/58 had metastatic disease. All patients received intensive polychemotherapy including VP-16 IV as first- (n = 53) or second-line (n = 5) treatment; 21/58 had myeloablative regimens with peripheral blood stem cell rescue, and 1 underwent allogeneic stem cell transplantation. Oral VP-16 was prescribed as 2nd-, 3rd-, and 4th-line treatment for 19, 27, and 12 patients, respectively. The cycles administered totaled 241 (median 3, mean 4 per patient; range 1-14). A total of 46 of 58 patients were evaluable: 11 responded (9 partial remission, 1 very good partial remission, 1 complete remission) and 10 were stable, the response lasting a mean of 8 months. Hematologic toxicity G3/G4 (in 164/241 évaluable cycles) occurred in 15%, 16%, and 11% of cycles for leukocytes, hemoglobin, and platelets, respectively. There were 5 cases of pneumonia. Two patients developed secondary leukemia after receiving 12 and 14 cycles. Conclusions: Low-dose oral VP-16 may be suitable in a palliative setting with an acceptable toxicity. The risk of secondary leukemia is in line with reports in the literature.

Original languageEnglish
Pages (from-to)84-88
Number of pages5
JournalTumori
Volume102
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Ewing's Sarcoma
Etoposide
Leukemia
Stem Cell Transplantation
Combination Drug Therapy
Disease Progression
Pneumonia
Hemoglobins
Leukocytes
Therapeutics
Blood Platelets

Keywords

  • Oral etoposide
  • Palliative care
  • Relapsing/refractory Ewing sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Oral etoposide in relapsed or refractory Ewing sarcoma : A monoinstitutional experience in children and adolescents. / Podda, Marta G.; Luksch, Roberto; Puma, Nadia; Gandola, Lorenza; Morosi, Carlo; Terenziani, Monica; Ferrari, Andrea; Casanova, Michela; Spreafico, Filippo; Meazza, Cristina; Catania, Serena; Schiavello, Elisabetta; Biassoni, Veronica; Chiaravalli, Stefano; Massimino, Maura.

In: Tumori, Vol. 102, No. 1, 01.01.2016, p. 84-88.

Research output: Contribution to journalArticle

@article{23a8eb85b79c48a8af2d97ef5dfcce14,
title = "Oral etoposide in relapsed or refractory Ewing sarcoma: A monoinstitutional experience in children and adolescents",
abstract = "Aims: To assess the efficacy and toxicity of low-dose oral etoposide (VP) 16 in relapsing/refractory Ewing sarcoma. Methods: The records of all patients treated at our department between 1989 and 2012 for relapsing/refractory Ewing sarcoma who received oral VP-16 were analyzed. The dose was 40 mg/m2 daily for 21 consecutive days in every 28. Response was assessed after 2/3 cycles according to Response Evaluation Criteria in Solid Tumors 1.0. Results: A total of 46 of 58 patients completed at least 2 cycles; 12 suspended the treatment earlier due to rapid disease progression. The patients' median age at diagnosis was 14 years and 25/58 had metastatic disease. All patients received intensive polychemotherapy including VP-16 IV as first- (n = 53) or second-line (n = 5) treatment; 21/58 had myeloablative regimens with peripheral blood stem cell rescue, and 1 underwent allogeneic stem cell transplantation. Oral VP-16 was prescribed as 2nd-, 3rd-, and 4th-line treatment for 19, 27, and 12 patients, respectively. The cycles administered totaled 241 (median 3, mean 4 per patient; range 1-14). A total of 46 of 58 patients were evaluable: 11 responded (9 partial remission, 1 very good partial remission, 1 complete remission) and 10 were stable, the response lasting a mean of 8 months. Hematologic toxicity G3/G4 (in 164/241 {\'e}valuable cycles) occurred in 15{\%}, 16{\%}, and 11{\%} of cycles for leukocytes, hemoglobin, and platelets, respectively. There were 5 cases of pneumonia. Two patients developed secondary leukemia after receiving 12 and 14 cycles. Conclusions: Low-dose oral VP-16 may be suitable in a palliative setting with an acceptable toxicity. The risk of secondary leukemia is in line with reports in the literature.",
keywords = "Oral etoposide, Palliative care, Relapsing/refractory Ewing sarcoma",
author = "Podda, {Marta G.} and Roberto Luksch and Nadia Puma and Lorenza Gandola and Carlo Morosi and Monica Terenziani and Andrea Ferrari and Michela Casanova and Filippo Spreafico and Cristina Meazza and Serena Catania and Elisabetta Schiavello and Veronica Biassoni and Stefano Chiaravalli and Maura Massimino",
year = "2016",
month = "1",
day = "1",
doi = "10.5301/tj.5000419",
language = "English",
volume = "102",
pages = "84--88",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Oral etoposide in relapsed or refractory Ewing sarcoma

T2 - A monoinstitutional experience in children and adolescents

AU - Podda, Marta G.

AU - Luksch, Roberto

AU - Puma, Nadia

AU - Gandola, Lorenza

AU - Morosi, Carlo

AU - Terenziani, Monica

AU - Ferrari, Andrea

AU - Casanova, Michela

AU - Spreafico, Filippo

AU - Meazza, Cristina

AU - Catania, Serena

AU - Schiavello, Elisabetta

AU - Biassoni, Veronica

AU - Chiaravalli, Stefano

AU - Massimino, Maura

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Aims: To assess the efficacy and toxicity of low-dose oral etoposide (VP) 16 in relapsing/refractory Ewing sarcoma. Methods: The records of all patients treated at our department between 1989 and 2012 for relapsing/refractory Ewing sarcoma who received oral VP-16 were analyzed. The dose was 40 mg/m2 daily for 21 consecutive days in every 28. Response was assessed after 2/3 cycles according to Response Evaluation Criteria in Solid Tumors 1.0. Results: A total of 46 of 58 patients completed at least 2 cycles; 12 suspended the treatment earlier due to rapid disease progression. The patients' median age at diagnosis was 14 years and 25/58 had metastatic disease. All patients received intensive polychemotherapy including VP-16 IV as first- (n = 53) or second-line (n = 5) treatment; 21/58 had myeloablative regimens with peripheral blood stem cell rescue, and 1 underwent allogeneic stem cell transplantation. Oral VP-16 was prescribed as 2nd-, 3rd-, and 4th-line treatment for 19, 27, and 12 patients, respectively. The cycles administered totaled 241 (median 3, mean 4 per patient; range 1-14). A total of 46 of 58 patients were evaluable: 11 responded (9 partial remission, 1 very good partial remission, 1 complete remission) and 10 were stable, the response lasting a mean of 8 months. Hematologic toxicity G3/G4 (in 164/241 évaluable cycles) occurred in 15%, 16%, and 11% of cycles for leukocytes, hemoglobin, and platelets, respectively. There were 5 cases of pneumonia. Two patients developed secondary leukemia after receiving 12 and 14 cycles. Conclusions: Low-dose oral VP-16 may be suitable in a palliative setting with an acceptable toxicity. The risk of secondary leukemia is in line with reports in the literature.

AB - Aims: To assess the efficacy and toxicity of low-dose oral etoposide (VP) 16 in relapsing/refractory Ewing sarcoma. Methods: The records of all patients treated at our department between 1989 and 2012 for relapsing/refractory Ewing sarcoma who received oral VP-16 were analyzed. The dose was 40 mg/m2 daily for 21 consecutive days in every 28. Response was assessed after 2/3 cycles according to Response Evaluation Criteria in Solid Tumors 1.0. Results: A total of 46 of 58 patients completed at least 2 cycles; 12 suspended the treatment earlier due to rapid disease progression. The patients' median age at diagnosis was 14 years and 25/58 had metastatic disease. All patients received intensive polychemotherapy including VP-16 IV as first- (n = 53) or second-line (n = 5) treatment; 21/58 had myeloablative regimens with peripheral blood stem cell rescue, and 1 underwent allogeneic stem cell transplantation. Oral VP-16 was prescribed as 2nd-, 3rd-, and 4th-line treatment for 19, 27, and 12 patients, respectively. The cycles administered totaled 241 (median 3, mean 4 per patient; range 1-14). A total of 46 of 58 patients were evaluable: 11 responded (9 partial remission, 1 very good partial remission, 1 complete remission) and 10 were stable, the response lasting a mean of 8 months. Hematologic toxicity G3/G4 (in 164/241 évaluable cycles) occurred in 15%, 16%, and 11% of cycles for leukocytes, hemoglobin, and platelets, respectively. There were 5 cases of pneumonia. Two patients developed secondary leukemia after receiving 12 and 14 cycles. Conclusions: Low-dose oral VP-16 may be suitable in a palliative setting with an acceptable toxicity. The risk of secondary leukemia is in line with reports in the literature.

KW - Oral etoposide

KW - Palliative care

KW - Relapsing/refractory Ewing sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84962799687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962799687&partnerID=8YFLogxK

U2 - 10.5301/tj.5000419

DO - 10.5301/tj.5000419

M3 - Article

C2 - 26797935

AN - SCOPUS:84962799687

VL - 102

SP - 84

EP - 88

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 1

ER -